Tvardi Therapeutics racks up $74m Series B

Tvardi Therapeutics Inc, a biopharmaceutical company, has secured $74 million in Series B financing.

23 June 2021•1 min read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles